Could This $3 Stock Disrupt the $12 Trillion Healthcare Industry?
Companies / Healthcare Sector Nov 02, 2021 - 03:16 PM GMTBy: Submissions
The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate.
And in the bigger scenario of a massive $11-trillion-plus global healthcare industry, America is definitely not first.
Americans are fed up, and a digital revolution that goes way beyond telemedicine is the only thing that will restore control.
Fixing it is a highly disruptive, multi-trillion-dollar opportunity.
Telemedicine, or ‘Telehealth’, will soar from $42 billion in 2018 to $400 billion in 2026.
Healthcare IT alone will be worth $390 billion by 2024.
But the biggest disruptor of them all may be medical apps.
Source: Allied Market Research
And the advantage just might go to a Canadian company with perhaps the most sophisticated AI the healthcare sector has ever seen …
Now, it’s about to launch in North America. And plans to then go global. City by city.
The company is Treatment.com International Inc. (CSE: TRUE; OTC: TREIF) and the world has never seen anything like global library of medicine, nor CARA, the new doctor-developed AI that could be set to revolutionize the $11 trillion healthcare industry
CARA is personalized in every way. CARA, Treatment’s Digital Assistant assesses symptoms based on your actual information; CARA helps you to diagnose health problems, makes recommendations, tracks and monitors your symptoms and follows up with your healthcare every step of the way. From cradle to grave, CARA helps you and your entire family (including caregivers) manage healthcare.
The technology is 100% proprietary and it’s ready to win over a massive consumer base that is begging for a healthcare revolution.
THIS IS THE NEW STANDARD IN AI HEALTHCARE
Medical apps are tapped to be the fastest-growing IT healthcare segment, with consumers starving for better services that they can actually control and understand.
We’re just at the beginning of a complete revolution in the healthcare industry, and Treatment.com is the first to truly attempt to empower the consumer with AI that thinks like a doctor because it was trained by real doctors over the past six years.
The team behind it has a near perfect track record in building and scaling IT infrastructure, particularly in the healthcare sector, with major rewards for investors.
For the past 6 years, a team of over 40 global world-class medical experts have been working to build the AI infrastructure for CARA and Treatment.com International Inc. (CSE: TRUE; OTC: TREIF).
The AI is already so sophisticated it’s been licensed by the University of Minnesota Medical School to teach and test medical students.
SCALING A HEALTH TECH STARTUP TO A BILLION DOLLAR EXIT
John Fraser, the co-founder and CEO of Treatment.com, is a 20-year software IT veteran, who has been laser focused on the healthcare industry, launching his career at the Minnesota Department of Health.
He was the key architect of a statewide cancer surveillance system (at the time – the largest ever conducted in the world). He created an entire pathology-based library of everyone in Minnesota with cancer. It was the first time in IT history that anyone had attempted an endeavor of that magnitude. And it proved an invaluable resource that is still used today.
Fraser took that success and ran with it, becoming a big name in the unicorn space, and an expert at scaling up tech products and building valuable intellectual property (IP). His first unicorn was Vision Share (now Abilities Network), an IT claims and eligibility service that upended insurance claim management and healthcare billing. Vision Share sold for over $1.2 billion in 2015.
What he did with Vision Share was just the precursor to Treatment.com, and CARA. He built an IT claims and eligibility service that was adopted across the country and is now among the top providers to payers and insurance providers in the United States.
And he’s not the only pioneer behind Treatment.com.
This is an expert executive and management team that has formed the backbone of the ailing healthcare industry’s service revolution.
Co-founder and chief medical officer Dr. Kevin Peterson is an IT healthcare superstar with 35 years experience at the University of Minnesota, where he built the ECRN system to fully automate clinical studies at scale. He is an expert in chronic disease management, health services, diabetes, bioinformatics and clinical trials in primary care.
The company’s Chief Strategy Officer, Dr Paul Markham a veteran and influencer in the global healthcare tech space is driving the next phase of growth at Treatment.com.
And AI pioneer David Poole, Treatment.com’s Director of AI Research, is a professor of Computer Science at the University of British Columbia and the chair of the Association for Uncertainty in Artificial Intelligence, as well as Fellow of the Association for the Advancement of Artificial Intelligence (AAAI). He was also bestowed the Canadian AI Association (CAIAC) Lifetime Achievement Award in 2013.
THE RUSH FOR IT HEALTHCARE SOLUTIONS HAS ALREADY BEGUN
This space is heating up—fast.
UK-based Babylon Health, a telehealth startup, is set to go public in the U.S. via a $4.2-billion SPAC deal.
Big money should be looking for better deals than this, though. Deals that prioritize and emphasize artificial intelligence.
That’s what makes Babylon less attractive than it could be, says Treatment.com’s Dr. Keven Peterson.
“Babylon has struggled to provide an effective [AI powered] clinical decision support product. Their revenues are based on their clinical telemedicine, which uses the weakness of their app to draw people into the telemedicine interaction,” Peterson said, commenting on the $4.2-billion SPAC deal.
Treatment.com International (CSE: TRUE; OTC: TREIF) offers digital capabilities powered by AI that are stronger than anything thrown at the market to date.
“Our stronger digital capabilities give us an edge on customer engagement. Furthermore, completion of our medical product will engage medical systems by providing powerful clinical decision support. Ultimately, our more powerful AI tool and greater provider engagement should give us a substantial competitive edge over this provider,” Peterson added.
ADA Health is another new entrant in this exciting space, and it recently closed a $90-million funding round led by Bayer and Samsung, and it’s partnering with Novartis. In 8 months, it’s managed to sign on 10 new global partners, thanks in large part to the allure of its AI powered symptom assessment technology.
Medical apps powered by AI are poised to explode precisely because the AI brings everything together, intelligently.
This is where TRUE has the competitive edge.
“This vast infrastructure works to simplify an incredibly complex picture that is given from the patients input and historical data,” says John Fraser, CEO of TRUE. “The AI absorbs all of the users inputs and background information and applies it to current symptomology – and then thinking like a doctor –provides a comprehensive and hyper-personalized diagnostic assessment with suggestions for immediate treatment and healing.”
THIS TECH WON’T BE UNDER THE RADAR FOR LONG
Americans are desperate for healthcare clarity; Treatment.com gives it to them. Googling symptoms does not.
CARA isn’t a game of googling symptoms and coming up with the most-searched piece of potential, anxiety-causing misinformation. CARA uses your medical records and the power of sophisticated AI trained by doctors to assess your symptoms and get you the care that you need, seamlessly.
But for investors, the opportunity may be far bigger. TRUE has both B2C and B2B capabilities.
On the B2C side, Treatment.com is laser focused on leveraging AI powered CARA to empower individuals to gain control over their health and wellbeing.
On the B2B side, the massive global health insurance market, surging toward $4 trillion, is likely to find CARA a goldmine of data, predictability and scalability. And remember, Fraser has experience with scaling businesses through these kinds of partnerships, having founded $1.2 billion healthcare SaaS unicorn Ability Networks – that scaled through insurance partnerships.
All of this makes the underlying, 100% owned proprietary IP something that should have investor interest piqued. Keep this name on your radar as Treatment.com International (CSE: TRUE; OTC: TREIF) plans to launch it’s ground-breaking APP – ‘CARA’ – powered by the most comprehensive AI in the industry, before the end of this year.
Other companies taking on the world’s health crises in their own way:
Sage Therapeutics (NASDAQ:SAGE) is an incredible example of a company using its immense resources and knowhow to tackle the growing health crisis in the United States and abroad. With a focus on exciting new ways to treat mental health disorders, the company released the only FDA-approved treatment for post-partum depression. It's drug, Zulresso, soared through clinical trials with no issues, and is advertised to help mothers feel better in just 2.5 days. The drug is administered under the careful guidance of professionals in their specialized treatment centers and has been a huge success for Sage.
Dr. Jeffrey Cohen founded Sage Therapeutics in 2003 with a mission to discover and develop life-saving medicines for rare diseases. The company has gone on create treatments that have been approved all around the world, including Pompe disease, Sanfilippo syndrome type A (a form ofalthouhough largely affecting children), Fabry disease as well Gaucher Disease which can be hereditary or caused by environmental factors such food intolerance issues like gluten sensitivity among others . These therapies are changing lives every day while also making us more aware than ever before about these healthcare needs.
Cassava Sciences (NASDAQ:SAVA) is a clinical-stage biopharmaceutical company focused on neurosciences. They are committed to advancing neuroscience research and developing novel therapies for patients with brain disorders. The founders of Cassava Sciences have an extensive background in both biotechnology and the pharmaceutical industry, which gives them the expertise needed to lead the company into its next phase of growth.
Cassava Sciences was founded by two scientists who worked together at Pfizer Pharmaceuticals for over 20 years before they left the company in 2015 to start their own biotech startup, one that would focus on solving some of medicine's most difficult problems. Since then, they've recruited a team of likeminded individuals with deep scientific experience, as well as key partnerships with leading universities around the world.
COMPASS Pathways plc (NASDAQ:CMPS) offers assessment, treatment and rehabilitation services to both adults and children in the UK, Ireland, Australia and New Zealand. These include community-based treatment programs that are tailored to meet the individual needs of their clients. Mental Health Division CEO Dr. Karen Kennedy has led Compass Pathways plc since 2006 when she joined as Chief Executive Officer from her previous position at Southern Cross Healthcare Group Limited where she was also Chief Executive Officer. She holds degrees in Medicine, Nursing Science, Economics and Psychology from Trinity College Dublin; University College Dublin; University of Sydney; York University (Canada) respectively which provides her with an all-round understanding of healthcare systems.
CMPASS Pathways’ COMP360 solution has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and the company is currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. COMPASS’ meticulous approach to psilocybin treatments is important because, while legalization may look imminent, there’s still a long road ahead for this relatively new medicine.
CEO George Goldsmith explained. "There simply isn't yet enough evidence of safety and efficacy of psilocybin therapy, which is why we're doing our trials," adding "the review and approval to regulatory agencies is really the best way ensure the safety, efficacy and quality of any medicine or therapy.”
Neuronetics, Inc. (NYSE:STIM) is a pioneer of neuromodulation therapies that are used to treat neurological disorders. Neuronetics was founded in 1993 and has introduced numerous innovative solutions for neuropsychiatric conditions such as depression, anxiety, obsessive-compulsive disorder (OCD), chronic pain, posttraumatic stress disorder (PTSD), Parkinson's disease, epilepsy and Alzheimer’s disease. The company offers both deep brain stimulation systems and VNS Therapy® which have helped improve the lives of thousands suffering from debilitating neurological or psychiatric diseases.
Neurometics’ products are based on a proprietary delivery platform that uses low-intensity electrical currents to stimulate nerve cells in the brain using electrodes on the surface of the head or via implanted leads directly into targeted areas of the nervous system. Neuronetics has developed both investigational devices and FDA-approved therapeutic devices for use in clinical trials, including deep brain stimulation (DBS) therapy for Parkinson’s disease, essential tremor, dystonia and other movement disorders; peripheral nerve field stimulation (PNFS) therapy for chronic neuropathic pain; vagus nerve stimulator therapy for epilepsy treatment-resistant depression among many others.
Neuronetics Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The company’s first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
Neuronetics’ TouchStar protocol is a non-drug, non-invasive transcranial magnetic stimulation (TMS) treatment for Major Depressive Disorder (MDD). Greg Harper, Vice President of Product Development and Operations at Neuronetics, explained, The TouchStar protocol is particularly impactful when paired with our patented Contact Sensing precision technology that provides clinicians with the confidence of knowing they are giving patients the right dose at the exact location."
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is a company that provides healthcare services in the United States. The company offers medical management for post-acute care and rehabilitation needs of patients after they have been discharged from hospital settings or skilled nursing facilities. Acadia's offerings include anesthesiology; cardiopulmonary; clinical pharmacy; diagnostic imaging (CT, MRI); laboratory (blood chemistry, hematology); long-term acute care/rehabilitation; occupational therapy; physical therapy and speech pathology.
Acadia also operates two hospitals: Bay Medical Center in Panama City Beach, Florida and Gulf Coast Medical Center in New Port Richey, Florida
Acadia Healthcare also offers a wide range of behavioral health and addiction services to its patients through the use of evidence-based treatment methods. The company is primarily focused on providing a continuum of care for individuals in need with mental health and substance abuse related issues by developing personalized treatment plans that are designed to meet the specific needs of each individual they serve, while also providing support for family members or friends who may be involved in their recovery process.
The impact of psychedelics on mental health has been a subject of interest for decades. For some, the symptoms of anxiety and depression are alleviated by these substances' ability to alter perception and promote spiritual exploration, and Canada-based Field Trip Health (CSE:FTRP) is taking a lead in this emerging field. Field Trip taking a three-pronged approach in their work in the transformative psychedelic medicine sector. Not only are they involved in drug development, but they’re also involved in manufacturing and run a number of treatment clinics.
Field Trip has hit the ground running. With clinics currently operating in Toronto, Los Angeles, and New York, they have plans to ramp up to 75 clinics – providing psychotherapy along with psychedelic treatments.
In the past, pharmaceutical companies have been limited to marketing their drugs through prescription-only channels. This limits the marketing potential and the ability for a company to reach a large audience. Trillium Therapeutics Inc. (TSX:TRIL) has found a way to bypass this limitation by using biotechnology. They take live cells from animals and grow them in large amounts for use as medicine. The process is called "pharming" or "transgenic." It's an innovative approach that could change how we think about drug development and distribution of medicines worldwide.
Trillum is a specialized biotechnology company that takes a unique approach on the industry, harnessing insights from nature to develop novel immunotherapies to treat cancer. Trillium’s products tackle such diseases as lymphoma and myeloma and other blood cancers.
Oncolytics Biotech Inc. (TSX:ONC) is a biotechnology company specializing in the development of novel, smallpox-derived oncolytic viral therapies for cancer treatment. The company's lead product candidate, Toca 511 & Toca FC, has been granted Fast Track designation by the FDA for the treatment of patients with metastatic melanoma that cannot be removed by surgery or radiation therapy. Oncolytics Biotech Inc is committed to developing innovative therapies that address significant unmet medical needs and have the potential to significantly improve outcomes for patients with serious infections and cancer.
Oncolytics Biotech got it start from a major series of discoveries based out of the University of Calgary and has grown significantly over the past two decades. Onoclytics’ primary product is REOLYSIN, a first-in-class, systemically administered, immuno-oncolytic virus created with the potential to act as a therapy for cancer patients.
Namaste Technologies Inc (TSX.V:N) is a Canadian company that develops and sells innovative cannabis products, like the NamasteMD mobile app that connects Canadians to medical cannabis doctors and allows them to order securely online. They also provide "Namaste Vapes," which are vaporizers with no THC or CBD, but offer a variety of aromatherapy options.
This company has been experiencing exponential growth in recent years thanks to their unique product offerings and dedication to improving access for patients seeking medical marijuana treatment through innovation.
Through its subsidiaries, Namaste Technologies operates as a retailer of a variety of marijuana products, including vaporizers and other smoking accessories. The company sells its goods through e-commerce sites operating in 26 countries. In addition to its accessory business, Namaste also engages in product development and the distribution of medical cannabis products in Canada.
The Hexo Corporation (TSX:HEXO), a Canadian company originally founded as Hydropothecary Corp., has been developing and distributing medical marijuana products since 2013. In 2017, it was the first cannabis producer approved to list its shares on a major North American stock exchange. The company is now gearing up for legalization of recreational use by adults in Canada next year with plans to offer a range of adult-use products.
In Hexo’s fourth-quarter press release, the company shared some optimistic news regarding Truss’ progress, with Sebastien St-Louis, Hexo CEO and co-founder, explaining, “We are commanding significant market share in Quebec and this year we made major strides by launching Truss cannabis infused beverages in Canada in addition to our initial foray into the U.S. with Molson Coors, a world-class partner,”
By. William Thomas
** IMPORTANT NOTICE AND DISCLAIMER -- PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT. This article is a paid advertisement. GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher four hundred and fifty thousand US dollars to produce and disseminate four articles profiling the Company. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s to be launched health and wellness app – “CARA”, the reported scheduled release of CARA, the ability to acquire customers for CARA, and the projected growth and profit margins of the Company’s core product offerings. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the launch of CARA, competition, market saturation, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.
